

# Drug candidate for weight management, with preventive and curative effects on CV and metabolic risks



- Normalisation of weight gain
- First drug acting on several components of cardiovascular and metabolic risk (metabolic syndrome) simultaneously

## KEYWORDS

Cardiovascular and  
metabolic risk  
Monotherapy  
I<sub>1</sub> imidazole receptor  
Obesity

## PATENTS

FR 1153375

19/04/2011

WO/2012/143660

filed on April 17, 2012

National phases

IN/JP/CA

Granted

EP/CN/US

## INVENTORS

Bousquet P.

Erhardt J.D.

Mann A.

Gasparik V.

Schann S.

Hadjeri M.

Niederhoffer N.

Fellmann L.

Grenay H.

Strasbourg, FR

Université de Strasbourg



## TECHNOLOGY

- Chemical derivatives of imidazolines and oxazolines, which selectively target the I<sub>1</sub> imidazoline receptors
- Devoid of  $\alpha_2$ -AR activity
- Prevention of weight increase in multiple animal models
- Combined action on hypertension, insulin resistance, glucose tolerance, and lipid metabolism in several animal models
- Wide therapeutic window, no detectable toxicity at active doses in murine models

## APPLICATIONS

- Overweight/obesity treatment
- Primary prevention and/or treatment of cardiovascular and metabolic risk (metabolic syndrome)

## INNOVATION ADVANTAGES

- Best-in class candidate displaying higher efficacy on metabolic risk factors and lower side effects
- I<sub>1</sub> - agonism demonstrated to be safe in large-scale clinical studies and > 15 years of postmarketing experience
- First potential metabolic treatment for metabolic syndrome reducing risk for DDIs related to polypharmacy
- First potential monotherapy treatment, while current treatments consist of combination of 3 to 6 drugs
- Higher tolerance, better observance and lower cost expected

## DEVELOPMENT STATUS

- Preclinical data package in rodents available (PK, PD, TOX)
- Study on non human primate model ongoing

*Partnership : Seeking partners to license the technology*

## CONTACT

Vincent Bischoff

Business Developer (Santé)

(+ 33) 3 68 41 12 66 - [vincent.bischoff@satt.conectus.fr](mailto:vincent.bischoff@satt.conectus.fr)

Parc d'Innovation

650 Bd Gonthier d'Andernach

67400 ILLKIRCH - FRANCE

[www.satt.conectus.fr](http://www.satt.conectus.fr)